These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18451015)

  • 1. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006.
    Alessi-Severini S; Biscontri RG; Collins DM; Kozyrskyj A; Sareen J; Enns MW
    Psychiatr Serv; 2008 May; 59(5):547-53. PubMed ID: 18451015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years of antipsychotic prescribing to children: a Canadian population-based study.
    Alessi-Severini S; Biscontri RG; Collins DM; Sareen J; Enns MW
    Can J Psychiatry; 2012 Jan; 57(1):52-8. PubMed ID: 22296959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic use in the elderly: shifting trends and increasing costs.
    Rapoport M; Mamdani M; Shulman KI; Herrmann N; Rochon PA
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):749-53. PubMed ID: 16035128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing of antipsychotics in UK primary care: a cohort study.
    Marston L; Nazareth I; Petersen I; Walters K; Osborn DP
    BMJ Open; 2014 Dec; 4(12):e006135. PubMed ID: 25524544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience.
    Dewa CS; Remington G; Herrmann N; Fearnley J; Goering P
    Clin Ther; 2002 Sep; 24(9):1466-76. PubMed ID: 12380638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada.
    Janzen D; Bolton J; Kuo IF; Leong C; Alessi-Severini S
    J Clin Psychopharmacol; 2020; 40(1):6-13. PubMed ID: 31834085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002.
    Mirandola M; Andretta M; Corbari L; Sorio A; Nosè M; Barbui C
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):412-20. PubMed ID: 16287199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes.
    Leslie DL; Rosenheck RA
    Psychiatr Serv; 2005 Jul; 56(7):803-9. PubMed ID: 16020811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.
    Latimer EA; Naidu A; Moodie EE; Clark RE; Malla AK; Tamblyn R; Wynant W
    Psychiatr Serv; 2014 Oct; 65(10):1210-7. PubMed ID: 24981557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
    De Beauchamp I; Giraud-Baro E; Gury C
    Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
    [No Abstract]   [Full Text] [Related]  

  • 16. NAMI perspective on CATIE: policy and research implications.
    Duckworth K; Fitzpatrick MJ
    Psychiatr Serv; 2008 May; 59(5):537-9. PubMed ID: 18451013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups.
    Lao KSJ; Tam AWY; Wong ICK; Besag FMC; Man KKC; Chui CSL; Chan EW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1387-1394. PubMed ID: 28665012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S; Assion HJ; Stargardt T; Busse R; Juckel G; Gericke CA
    Pharmacopsychiatry; 2009 Mar; 42(2):66-71. PubMed ID: 19308881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia.
    Luo RD; Belleti DA; Tran D; Arcona S; Salen PN
    Int J Psychiatry Med; 2002; 32(3):261-9. PubMed ID: 12489701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.